Bioventus Inc. (BVS)Healthcare | Medical Devices | Durham, United States | NasdaqGS
10.57 USD
+0.15
(1.489%)
⇧
(April 17, 2026, 2:30 p.m.
EDT)
Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 2:53 p.m. EDT
Bioventus Inc. (BVS) is currently in a range-bound trading pattern with a slight upward trend, but the overall fundamentals and dividend yield are not strong enough to justify a high star rating. The stock has shown some momentum in recent days, but the lack of dividends and mixed options activity suggest caution. While the stock may offer a short-term buying opportunity, long-term investors should consider the high debt-to-equity ratio and moderate growth prospects. The current price is near the 52-week low, which could present a potential dip buying opportunity for short-term traders, but long-term investors should wait for more positive earnings and fundamentals. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.097147 |
| AutoARIMA | 0.103994 |
| MSTL | 0.104792 |
| AutoETS | 0.106183 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 9.84 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.027 |
| Excess Kurtosis | 1.45 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 136.288 |
| Revenue per Share | 8.527 |
| Market Cap | 711,743,424 |
| Trailing P/E | 32.02 |
| Forward P/E | 12.14 |
| Beta | 0.69 |
| Profit Margins | 4.00% |
| Website | https://www.bioventus.com |
As of April 11, 2026, 2:53 p.m. EDT: Options speculators are showing mixed signals. Calls are more active, with higher open interest (OI) and volume on out-of-the-money (OTM) strikes, indicating potential for upward movement. However, puts have higher implied volatility (IV) on in-the-money (ITM) strikes, suggesting some bearish sentiment. The overall options activity suggests a cautious outlook, with traders possibly hedging against downside risk while anticipating some upward momentum.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.388 |
| Address1 | 4,721 Emperor Boulevard |
| Address2 | Suite 100 |
| All Time High | 19.941 |
| All Time Low | 0.8 |
| Ask | 10.85 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 486,460 |
| Average Daily Volume3 Month | 383,706 |
| Average Volume | 383,706 |
| Average Volume10Days | 486,460 |
| Beta | 0.693 |
| Bid | 10.59 |
| Bid Size | 1 |
| Board Risk | 5 |
| Book Value | 2.744 |
| City | Durham |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 10.565 |
| Current Ratio | 1.701 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 10.76 |
| Day Low | 10.46 |
| Debt To Equity | 136.288 |
| Display Name | Bioventus |
| Earnings Call Timestamp End | 1,772,717,400 |
| Earnings Call Timestamp Start | 1,772,717,400 |
| Earnings Timestamp | 1,772,717,400 |
| Earnings Timestamp End | 1,777,984,200 |
| Earnings Timestamp Start | 1,777,984,200 |
| Ebitda | 77,641,000 |
| Ebitda Margins | 0.13667 |
| Enterprise To Ebitda | 12.954 |
| Enterprise To Revenue | 1.77 |
| Enterprise Value | 1,005,751,424 |
| Eps Current Year | 0.7525 |
| Eps Forward | 0.87 |
| Eps Trailing Twelve Months | 0.33 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.8468 |
| Fifty Day Average Change | 1.7181997 |
| Fifty Day Average Change Percent | 0.19421709 |
| Fifty Two Week Change Percent | 38.800003 |
| Fifty Two Week High | 10.76 |
| Fifty Two Week High Change | -0.19500065 |
| Fifty Two Week High Change Percent | -0.018122736 |
| Fifty Two Week Low | 5.81 |
| Fifty Two Week Low Change | 4.7549996 |
| Fifty Two Week Low Change Percent | 0.8184165 |
| Fifty Two Week Range | 5.81 - 10.76 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,613,053,800,000 |
| Float Shares | 33,331,017 |
| Forward Eps | 0.87 |
| Forward P E | 12.143678 |
| Free Cashflow | 28,154,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 930 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.68327004 |
| Gross Profits | 388,156,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.118219994 |
| Held Percent Institutions | 0.78309 |
| Implied Shares Outstanding | 67,368,052 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,021-02-11 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina. |
| Long Name | Bioventus Inc. |
| Market | us_market |
| Market Cap | 711,743,424 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_154172707 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 22,732,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 700,627,740 |
| Number Of Analyst Opinions | 5 |
| Open | 10.708 |
| Operating Cashflow | 74,673,000 |
| Operating Margins | 0.13757 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 919 474 6700 |
| Previous Close | 10.41 |
| Price Eps Current Year | 14.039866 |
| Price Hint | 2 |
| Price To Book | 3.8502185 |
| Price To Sales Trailing12 Months | 1.2528776 |
| Profit Margins | 0.040009998 |
| Quick Ratio | 1.119 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.15499973 |
| Regular Market Change Percent | 1.4889504 |
| Regular Market Day High | 10.76 |
| Regular Market Day Low | 10.46 |
| Regular Market Day Range | 10.46 - 10.76 |
| Regular Market Open | 10.708 |
| Regular Market Previous Close | 10.41 |
| Regular Market Price | 10.565 |
| Regular Market Time | 1,776,450,658 |
| Regular Market Volume | 325,014 |
| Return On Assets | 0.049889997 |
| Return On Equity | 0.13174 |
| Revenue Growth | 0.028 |
| Revenue Per Share | 8.527 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 67,368,052 |
| Shares Percent Shares Out | 0.0228 |
| Shares Short | 1,533,910 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,436,599 |
| Short Name | Bioventus Inc. |
| Short Percent Of Float | 0.0582 |
| Short Ratio | 3.15 |
| Source Interval | 15 |
| State | NC |
| Symbol | BVS |
| Target High Price | 16.0 |
| Target Low Price | 14.0 |
| Target Mean Price | 14.8 |
| Target Median Price | 15.0 |
| Total Cash | 51,238,000 |
| Total Cash Per Share | 0.761 |
| Total Debt | 311,345,984 |
| Total Revenue | 568,086,976 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.33 |
| Trailing P E | 32.01515 |
| Trailing Peg Ratio | 1.3775 |
| Triggerable | 1 |
| Two Hundred Day Average | 7.5967 |
| Two Hundred Day Average Change | 2.9682994 |
| Two Hundred Day Average Change Percent | 0.39073536 |
| Type Disp | Equity |
| Volume | 325,014 |
| Website | https://www.bioventus.com |
| Zip | 27,703 |